ClinicalTrials.gg
CompletedNCT02033837Updated Aug 22, 2017

Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT

An observational study in Coronary Artery Disease and Cardiac CT, sponsored by Kumamoto University. Completed at 1 site in Japan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by Kumamoto University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
309
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.

Enrollment
23rd of 34
309 · median 431
Started
2013
with 10 others
Observational
34 of 134
4 open now
Registered
71st of 134
by date
Lead sponsor
7 of 134
Kumamoto University

Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 23rd largest by enrollment of the 34 observational ones that give a count, is one of 11 that started in 2013, is one of 34 observational ones, and was the 71st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Coronary Artery Disease with a site in Japan, or all of them as a file.
02

Study summary

The influence of the second-generation 320-row area-detector CT (ADCT) on the clinical indications and appropriateness of cardiac CT has not been adequately investigated. The purpose of the survey is to assess the distribution of appropriateness ratings and test outcomes of cardiac CT with second-generation ADCT.

03

Conditions studied

  • Coronary Artery Disease
  • Cardiac CT

Keywords

  • Coronary artery disease
  • Cardiac CT
  • Appropriate Use Criteria (AUC)
04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive patients referred for coronary CT angiography at our hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • indicated for coronary CT assessment

Exclusion criteria

Exclusion Criteria:

  • aortic disease
  • pulmonary embolism
  • severe arrhythmia
  • severe heart failure
  • allergy for iodinated contrast agent
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
309 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. significant coronary stenosis

    Time frame: one year

07

Study locations

1 site
  • Kumamoto University
    Kumamoto, 8608556, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2014
First posted
Jan 13, 2014
Start
Jan 2013
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Last update
Aug 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02033837
Lead sponsor
Kumamoto University
Responsible party
Daisuke Utsunomiya (Lecturer, Kumamoto University) — Principal investigator
First posted
Jan 13, 2014
Start date
Jan 2013
Primary completion
Aug 2017
Completion
Aug 2017
Last update
Aug 22, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion